Dr. Bulent Ozpolat , M.D., Ph.D., Associate Professor
MD Anderson Cancer Center-
The University of Texas-Houston
Department of Experimental Therapeutics
Title of the Talk; “ Development of Novel targeted therapies for Breast Cancers”
Currently breast cancer is most commonly diagnosed cancer in women. Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and associated with poor patient survival and high mortality rates. Due to highly heterogeneous genetic feature of the diseases has prevented identification of therapeutic targets and development of targeted therapies for TNBC . We recently discovered that eEF-2 Kinase (eEF2K) is highly overexpressed in TNBC patients and its expression is associated with significantly shooter patient survival. Using in vitro and in vivo tumor models in mice, we demonstrated that eEF2K promotes cell proliferation, invasion, metastasis and tumorigenesis. We also developed siRNA, microRNA-based therapeutics and demonstrated for the first time that in vivo targeting of this previously untargeted kinase by systemic administration inhibits tumor growth in several preclinical TNBC tumor xenograft models. The talk will also give background in targeted therapies used in cancer patients and our novel targeted therapies.
Dr. Bulent Ozpolat is serving as a Professor at the Department of Experimental Therapeutics at MD Anderson Cancer Center, The University of Texas-Houston, TX, USA. After getting his M.D. degree from The University of Dokuz Eylul University Medical School, Izmir, Turkey, Dr. Ozpolat received his Ph.D. degree in Immunology from the Graduate program at The M. D. Anderson Cancer Center—The University of Texas. Dr. Ozpolat completed his post doctoral training at MD Anderson Cancer Center at Houston Medical Center and specialized in Cancer biology, Genetics, Gene therapy, Nanotechnology and development of highly targeted targeted therapeutics.
Dr. Ozpolat’s laboratory at MD Anderson currently focuses on 1) identification of molecular targets in highly aggressive cancers such as breast, pancreatic ovarian 2) Development of highly targeted therapeutics (including gene silencing therapies and small molecule inhibitors) for EF2K and other targets.
Dr. Ozpolat is a member of Center for Targeted Therapy (CTT) and Non-Coding RNA center at MD Anderson Cancer Center and Graduate School of Biomedical sciences at The University of Texas. Dr received many research awards in recognition of research excellence. Dr. Ozpolat has 3 patents and published more than 90 publications (60 papers, 9 book chapter sand 14 review articles) in peer-reviewed high impact journals such as New England J of Medicine, Cell, Nature, Oncotarget, Cell Death and disease, Cancer Research, Clinical Cancer Research, Apoptosis, Molecular Cancer Therapeutics, Autophagy, J of Internal Medicine etc ) and contributed to textbooks. Dr. currently serve as an editor , associate editor and editorial board members of several journals ( ie, Translational Genetics and Genomics, Nanomedicine & Nanotechnology, Advances in Modern Oncology Research) and international External Advisory board of several Turkish Universities and work as a reviewer for US Congressionally Directed Medical research Department of Defense-Breast cancer and Immunology study sections, Italian health Ministry-Cancer, and Polish academy of Science and British Cancer Foundation.